NSETrading Window28 Sept 2026 · 28 Sept 2026, 01:53 pm
Trading Window
Suraksha Diagnostic Limited · SURAKSHA
✦ AI SummaryRegulatory
Suraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed for all designated persons and their immediate relatives from Thursday, 01st October, 2026, and shall remain closed till 48 hours after the declaration of unaudited (standalone and consolidated) financial results of the Company for the quarter and half year ended 30th September, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Suraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
SURAKSHA_28092026135316_Suraksha_Trading_Window_Closure_Intimation_for_Q2_FY_2026-27.pdf
View document text
Date: 28th September, 2026
The Secretary The Secretary
BSE Limited The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block
Dalal Street Bandra -Kurla Complex, Bandra (East)
Mumbai - 400 001 Mumbai- 400 051
Scrip Code: 544293 Scrip Symbol : SURAKSHA
Dear Sir / Ma’am,
Sub: Intimation of closure of trading window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from
time to time, we wish to inform you that in terms of the Company's Code of Conduct for regulating,
monitoring and reporting of trading by insiders, the trading window for dealing in securities of the
Company will remain closed for all designated persons and their immediate relatives from Thursday,
01st October, 2026 and shall remain closed till 48 hours after the declaration of unaudited (standalone
and consolidated) financial results of the Company for the quarter and half year ended 30th
September, 2026.
The aforesaid closure of the trading window has been intimated to all the designated person and
connected person in accordance with the Company’s Code of Conduct for Prohibition of Insider
Trading.
Further, the date of the meeting of the Board of Directors of the Company to consider and approve the
unaudited (standalone and consolidated) financial results of the Company for the aforesaid period
shall be intimated to the Stock Exchanges in due course.
The copies of the said publications are also available on the Company’s website at
www.surakshanet.com.
Kindly take the same on record.
Thank you.
Yours Faithfully,
For Suraksha Diagnostic Limited
Ritu Mittal
Joint Managing Director & CEO
DIN: 00165886
Encl: As above
Suraksha Diagnostic Limited
CIN: L85110WB2005PLC102265
Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New
Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com
Phone:(033) 6605 9750